Massachusetts Institute of Technology researchers have published an animal proof-of-concept study of their ingestible vital sign monitor that tracks heart and respiratory rates in real time.
Researchers from MIT--including drug delivery maven Robert Langer--and Massachusetts General Hospital have found a quick way to deliver drugs to the gastrointestinal tract using ultrasound, someday improving treatment of disorders there such as inflammatory bowel disease, ulcerative colitis and Crohn's disease.
Selecta Biosciences is taking another carefully planned step down the biotech path it set for itself, raking in $38 million in fresh venture cash from some prominent investors--including its close collaborator Sanofi--and paving the way through a key mid-stage study of its lead program.
Another one of Robert Langer's former grad students at MIT has leveraged a lab project into a new and fast-growing biotech. A mentoring relationship with the hyper-entrepreneurial star scientist and MIT's Klavs Jensen has put Armon Sharei at the head of a small biotech upstart--Boston-based SQZ Biotech--that hopes to largely replace decades of work on viral vectors with a new technology that's designed to quickly and easily put "stuff" inside a cell.
The millimeters-wide opening of the inner ear has long stymied efforts at drug delivery, but progress is being made, according to Scientific American. Draper Lab is working to create a small intracochlear device designed to treat hearing loss.
Researchers in the lab of MIT's Robert Langer have created a hydrogel that's designed to be much better than current technologies in getting drugs into patients and straight to where they are targeted.
MIT's Robert Langer took home the Queen Elizabeth Prize for his many contributions to drug delivery, including the development of controlled-release polymers, drug-delivering wafers and work on drug-eluting stents.
Not quite a venture firm, research institute or startup, PureTech is a bit of all three. The mission of the early stage research company just got a little bit easier--it bumped up its recent fundraising to $107 million from the $57 million it had raised as of October.
Cerulean Pharma announced last week that the first patient has received its Phase I/IIa cancer candidate, CRLX301, delivered using its RNA-based Dynamic Tumor Targeting Platform.
Microchips Biotech says it's ready to send its delivery technology out into the world, this week announcing it has completed development and clinical demonstration of the drug-delivering implant.